MENLO PARK, Calif.--(BUSINESS WIRE)--Avellino Labs, global biotechnology and genetic science innovators, announced today that Eric Donnenfeld, M.D., Edward Holland, M.D., Richard Lindstrom, M.D. and Elizabeth Yeu, M.D. have joined its board of medical advisors effective immediately.
“We have long benefitted from the expert input of the world-class clinicians, many of whom have been a part of the medical advisory team since Avellino Labs launched in 2008,” said Gene Lee, chairman of the board for Avellino Labs. “We are profoundly honored to welcome these respected ophthalmic surgeons to our Medical Advisory Board and look forward to their insights supporting our strategic market expansion.”
The latest additions to the Avellino Labs medical advisory board include some of the ophthalmic industry’s most recognizable and respected physicians and researchers. These U.S.-based opinion leaders have been instrumental in the development of the most widely implemented diagnostics and therapeutic treatments for the cornea, including refractive surgery. Collectively, their demonstrated abilities to develop science and share it in a meaningful way with the anterior segment community are the driving factors behind their appointments to the Avellino Labs medical advisory board.
Each clinician brings a specific focus on innovation and leadership which will support the development of Avellino Labs’ genetic technology to deliver more breakthrough products to the clinical practice and shape the future of personalized medicine in eye care:
Eric Donnenfeld, M.D. is a past president of the American Society of Cataract and Refractive Surgery and national medical director for TLC Laser Eye Centers. A clinical professor of ophthalmology at New York University Medical Center and chief medical editor of EyeWorld, Dr. Donnenfeld is a well-respected researcher and innovator in ophthalmology with a specific focus in refractive surgery with an extensive body of published work. Dr. Donnenfeld is a Fellow of the America Academy of Ophthalmology and practices at Ophthalmic Consultants of Long Island.
Edward Holland, M.D. is the director of cornea services at Cincinnati Eye Institute and professor of ophthalmology at the University of Cincinnati. He is a past president of the American Society of Cataract and Refractive Surgery, the Cornea Society and the Eye Bank Association of America. Dr. Holland is a recipient of the prestigious Binkhorst Medal (2008) and served on the Board of Trustees of the American Academy of Ophthalmology.
Richard L. Lindstrom, M.D., founder of Minnesota Eye Consultants, is an internationally-recognized leader in corneal, cataract and refractive surgery and sought-after keynote and guest lecturer before professional societies around the world. Known as a pioneer on the forefront of innovation in ophthalmology, Dr. Lindstrom holds more than 40 patents for pharmaceuticals and medical devices that are used in clinical practices globally and has made significant contributions to the science of ophthalmology through his published clinical research.
Elizabeth Yeu, M.D. of Virginia Eye Consultants is an assistant professor at the Eastern Virginia Medical School. She is editor-in-chief of U.S. Ophthalmic Review and is the medical editor for Millennial Eye. Dr. Yeu is a respected expert in refractive cataract surgery, anterior segment reconstruction and ocular surface disease and serves on several national medical boards and committees.
With today’s announcement, Avellino’s current medical advisory board now includes:
Anthony Aldave, M.D.
Andrea Cusumano, M.D.
Burkhard Dick, M.D.
Eric
Donnenfeld, M.D.
Edward Holland, M.D.
David Hwang, M.D.
E.K.
Kim, M.D., PhD
Terry Kim, M.D.
Shigeru Kinoshita, M.D.
Richard
Lindstrom, M.D.
Elizabeth Yeu, M.D.
About Avellino Labs
Avellino Labs is a global leader in gene therapy and molecular diagnostics and the pioneer in personalized medicine for eye care. Avellino Labs is pioneering CRISPR gene editing to manage and potentially cure inherited diseases. Avellino Labs continues to expand its diagnostics capabilities, building on the success of the world's first DNA test to confirm the presence of genetic indicators that are positively associated with corneal dystrophies, providing life-changing information for patient treatment decisions and follow-up care. Avellino Labs is headquartered in Silicon Valley, California, with operations in Korea, Japan, China and the UK.
Avellino Labs was named a 2015 Technology Pioneer by the World Economic Forum based on its potential to impact global health.
To learn more, please visit http://www.avellino.com/us/ or follow us on Twitter @Avellinolab_USA.
